Next up EVOLUS-- Evolus reports expansion into U.S. dermal filler market with Evolysse 05/09 EOLS Evolus announced it has entered into a definitive agreement to be the exclusive U.S. distributor of a line of five dermal fillers currently in late-stage development. The addition of a filler line expands the company's total addressable U.S. market by 70% by adding a $1.6 billion U.S. filler market opportunity to the existing $2.3 billion aesthetic neurotoxin market, with both markets expected to nearly double by 2028, the company said in a statement. As a result of this product expansion, the company has raised its 2028 revenue outlook by $200 million to $700 million. "Today's announcement represents a material step in achieving our goal of transforming Evolus into a multi-product aesthetics company," said David Moatazedi, Evolus' President and Chief Executive Officer. "We are excited to expand our portfolio with Evolysse(TM), a highly competitive filler line that complements our fast-growing aesthetic neurotoxin, Jeuveau(R). Injectables are the cornerstone of aesthetics with neurotoxins and dermal fillers as the top two aesthetic procedures in the U.S. Our customer-centric approach, existing digital infrastructure and distribution platform will power the launch of this innovative filler technology into the hands of our customers and their patients." Those dermal fillers are not on the market yet<--------- But assuming they make it the trigger action on EOLS could be huge! Look at these price targets- Evolus price target raised to $16 from $15 at H.C. Wainwright » Evolus price target raised to $18 from $14 at Truist 05/26 EOLS Truist analyst Gregory Fraser raised the firm's price target on Evolus to $18 from $14 and keeps a Buy rating on the shares as part of a broader research note on Pharmaceuticals. The analyst is updating the firm's model based on the sector's Q1 results, 10-Q filings, Rx trends, and deal activity. Truist is also boosting its expected 2023 revenue target for the company to $190M from $187M based on slightly higher Jeuveau share of the U.S. botulinum toxin market. And today our dear friend Mr Mizuho chimed in: Evolus price target raised to $20 from $17 at Mizuho 06:45 EOLS EOLS Evolus $8.74
$2.76 <-------- OR ----------> $5.50 Looking at the 1 year chart of D-Wave there is a large gap to fill! All the way to $5.60 this is going to be my target. But will it retrace first? If we get $2.60---$2.70 today we will have a big decision to make.
I may have to reconsider giving you guys the early action. I don't get enough thank you's. And now I am moving stocks. COYA took off.
UPDATE- COYA Coya Therapeutics, Inc. $4.340.14 (+3.33%)3:59 PM 06/06/23 NASDAQ | $USD | Pre-Market: $4.78 +0.44 (+10.14%) <--------8:36 AM
I was thinking how Van found ISRG in the singles before splits(2001-02), it’s probably worth millions now.
Extremely messy buyout situation over the pond.-- Low ball bids spoofing, Saudi dickering what the hell is going on with MANU? MANU Manchester United plc $18.410.36 (+1.99%)4:00 PM 06/06/23 NYSE | $USD | Pre-Market: $19.67 +1.26 (+6.84%) <---------- 8:36 AM
MODG Topgolf Callaway Brands Corp. $19.301.01 (+5.52%)4:00 PM 06/06/23 NYSE | $USD | Pre-Market: $19.69 +0.39 (+2.02%) 8:36 AM $21.60----$21.70 would fill the gap// not sure if that is enough.
Qatari Sheikh submits fifth and final bid for Manchester United, ESPN reports 08:50 MANU Qatari Sheikh Jassim made...
About 6 in the morn oil futures went nuts! This must be supply because China had downer news yet again... Crude Oil Jul 23 (CL=F) NY Mercantile - NY Mercantile Delayed Price. Currency in USD Follow 72.68+0.94 (+1.31%) As of 08:58AM EDT.